Introduction {#Sec1}
============

Approximatively 9000 surgical splenectomies are performed each year in France \[[@CR1]\], and the total number of French asplenic or hyposplenic persons is currently estimated to be between 250,000 and 500,000 \[[@CR1]\]. Asplenic patients are well-known to be at risk of post-splenectomy infections, mostly caused by *Streptococcus pneumoniae* \[[@CR2]--[@CR4]\]. Such infections may be characterized by a sudden onset and a fulminant course, leading to the so-called overwhelming post-splenectomy infection \[[@CR5]\]. A recent multicenter prospective study conducted in 173 German intensive care units (ICU) revealed that purpura fulminans, a rare cause of septic shock carrying high mortality and morbidity \[[@CR6], [@CR7]\], may develop in almost 20% of patients with overwhelming post-splenectomy infection \[[@CR2]\]. Furthermore, 22 to 32% of infectious purpura fulminans are due to *Streptococcus pneumoniae* \[[@CR6], [@CR8]\]. However, data on asplenic or hyposplenic patients with pneumococcal purpura fulminans are scarce, and individual vaccination status is rarely assessed. Moreover, there are only few studies comparing the clinical presentation and the outcome of patients with or without asplenia/hyposplenia admitted to the ICU for an overwhelming sepsis \[[@CR2]\].

We aimed to describe the clinical features and outcomes of adult patients admitted to the ICU for a pneumococcal purpura fulminans, according to the absence or presence of asplenia/hyposplenia.

Methods and patients {#Sec2}
====================

We performed an ancillary analysis of a 17-year national multicenter retrospective cohort study including adult patients (≥ 18 years old) admitted to 55 French ICUs for an infectious purpura fulminans from 2000 to 2016. Methods and patients have been previously described \[[@CR6]\]. An infectious purpura fulminans was defined by the association of a sudden and extensive purpura, evidence or high clinical suspicion of an infection, whatever its causative microorganism, together with acute circulatory failure needing vasopressor support. Patients with a noninfectious purpura and those with purpura in a context of infectious endocarditis were not included in the study. The investigator of each participating center was responsible for the identification of the patients, either from the hospital medical reports, using the function "research the files in which the word purpura fulminans occurs" of Microsoft Windows®, or through a search using the following International Classification of Diseases (10th Revision) codes: D65 (Disseminated intravascular coagulation), A39 (Meningococcal infection), A40 (Streptococcal sepsis), D65 (Disseminated intravascular coagulation), D69 (Purpura and other hemorrhagic conditions), and G00 (Bacterial meningitis). The hospital discharge reports of all identified patients were anonymized and then electronically or conventionally mailed to the main investigator (DC). Clinical charts were reviewed in order to check the inclusion criteria.

Only patients with pneumococcal (blood or cerebrospinal fluid cultures positive for *Streptococcus pneumoniae*, or positive pneumococcal urinary antigen testing) purpura fulminans were included in the present study. A patient was categorized as asplenic or hyposplenic when the medical records or the imaging performed during the ICU stay revealed the absence of spleen. Counting of Howell-Jolly bodies in peripheral blood smears was not routinely performed neither was the counting of pitted erythrocytes by phase-interference microscopy \[[@CR5]\]. Asplenic/hyposplenic patients were compared to eusplenic patients (defined as patients without asplenia or hyposplenia) admitted to the ICU for a pneumococcal purpura fulminans.

Collection of data {#Sec3}
------------------

Upon ICU admission and during ICU stay, data pertaining to demographics, comorbidities, clinical examinations, laboratory findings, microbiological investigations, and therapeutic management were collected. Simplified Acute Physiology Score II (SAPS II) \[[@CR9]\] and Sequential Organ Failure Assessment (SOFA) \[[@CR10]\] scores were computed using the worst values recorded within the first 24 h of admission. Missing data were retrieved from queries to the investigators. In asplenic/hyposplenic patients, the following data were retrieved from the ICU discharge reports: cause of asplenia (congenital or post-splenectomy in case of trauma, hematological diseases or cancer) or hyposplenia (splenic irradiation, sickle cell disease), time interval between asplenia/hyposplenia and ICU admission, presence or absence of antibiotic prophylaxis, and pneumococcal vaccination status.

Statistical analysis {#Sec4}
--------------------

Data were compared between asplenic/hyposplenic and eusplenic patients. Continuous variables were reported as median \[25th--75th interquartile range\] (IQR) or mean ± standard deviation (SD) and compared between groups using the Student *t* test or Mann-Whitney test, as appropriate. Categorical variables were reported as numbers and percentages (95% confidence interval, CI) and compared using *χ*^2^ test or Fisher's exact test, as appropriate. All statistical analyses were conducted using the SPSS Base 21.0 statistical software package (SPSS Inc., Chicago, IL.). A *p* value \< 0.05 was considered statistically significant.

Ethical considerations {#Sec5}
----------------------

This observational, non-interventional analysis of medical records was approved by the Institutional Review Board of the French Society of Intensive Care (FICS) in March 2016. As per French law, no informed consent was required for this type of study.

Results {#Sec6}
=======

Description of asplenic or hyposplenic patients with pneumococcal purpura fulminans {#Sec7}
-----------------------------------------------------------------------------------

Among the 306 patients admitted to the ICU for purpura fulminans, 67 (22%) had a pneumococcal purpura fulminans, of whom 34 (51%) had asplenia (*n* = 29/34, 85%) (Table [1](#Tab1){ref-type="table"}) or hyposplenia (*n* = 5/34, 15%) and 33 (49%) had eusplenia. Age, gender, and ICU severity scores did not differ between asplenic/hyposplenic and eusplenic patients (Table [2](#Tab2){ref-type="table"}). The prevalence of pneumococcal purpura fulminans was seven times higher in asplenic or hyposplenic patients compared to eusplenic patients with purpura fulminans (*n* = 34/39, 87% vs. *n* = 33/267, 12%; *p* \< 0.001) (Fig. [1](#Fig1){ref-type="fig"}). The main causes of asplenia were post-splenectomy (*n* = 26/29, 90%) and congenital (*n* = 3/29, 10%, two cases being diagnosed during ICU stay) (Table [1](#Tab1){ref-type="table"}**)**. Five patients had hyposplenia related to a splenic irradiation for lymphoma. The median time interval between asplenia/hyposplenia and ICU admission was 20 \[9--32\] years, with only 2/34 (6%) patients having pneumococcal purpura fulminans within the 2 years following splenectomy/hyposplenia (Table [1](#Tab1){ref-type="table"}). Only one patient (*n* = 1/32, 3%) (2 missing data) had received long-term antibiotic prophylaxis (time interval between splenectomy and ICU admission \< 1 year). Pneumococcal vaccination had been performed in 11/31 (35%) patients (3 missing data) (Table [1](#Tab1){ref-type="table"}). Among the 67 patients with pneumococcal purpura fulminans, 58 (87%) had positive blood cultures, 25 (37%) had a positive pneumococcal urinary antigen testing, and 11 of the 29 (38%) patients who had lumbar puncture had a positive CSF culture (Table [2](#Tab2){ref-type="table"}). Table 1Description of the 34 asplenic or hyposplenic patients with pneumococcal purpura fulminansHyposplenic or asplenic patients, *N* = 34Asplenia29/34 (85%)Hyposplenia5/34 (15%)Cause of asplenia Congenital3/29 (10%) Post-splenectomy26/29 (90%)  Trauma11/26 (42%)  Immune thrombocytopenic purpura6/26 (23%)  Pancreatic cancer3/26 (12%)  Left diaphragmatic hernia1/26 (4%)  Lymphoma1/26 (4%)  Myelodysplasia1/26 (4%)  Benign splenomegaly1/26 (4%)  Unknown1/26 (4%)Cause of hyposplenia Splenic irradiation5/5 (100%) Sickle cell disease0/5 (0%)Time interval between asplenia/hyposplenia and ICU admission, and pneumococcal vaccination coverage Time interval between asplenia/hyposplenia and ICU admission (years)20 \[9--32\] Time interval between asplenia/hyposplenia and ICU admission ≤ 2 years2/34 (6%) Time interval between asplenia/hyposplenia and ICU admission (years)\*19 \[9--30\] Time interval between asplenia/hyposplenia and ICU admission ≤ 2 years\*2/31 (6%) Long-term antibiotic prophylaxis1/32 (3%) Pneumococcal vaccination11/31 (35%)\*After exclusion of the three patients with congenital asplenia Table 2Comparison between patients with pneumococcal purpura fulminans having asplenia/hyposplenia (*n* = 34) or eusplenia (*n* = 33)Hypo/asplenia, *N* = 34Eusplenia, *N* = 33*p*Age, gender, and ICU scores Age, years48.9 ± 14.449.2 ± 14.10.83 Male gender22 (65)15 (45)0.11 SAPS II60 ± 1460 ± 180.24 SOFA13 \[12--16\]14 \[10--15\]0.48Comorbidities No coexisting comorbid conditions^a^24 (71)20 (61)0.39 Chronic respiratory disease1 (3)0 (0)0.32 Chronic heart failure1 (3)0 (0)0.32 Chronic kidney disease0 (0)0 (0)-- Cirrhosis0 (0)1 (3)0.31 Alcohol use2 (6)7 (21)0.07 Recent malignant hemopathy1 (3)1 (3)0.98 Recent cancer0 (0)0 (0)-- Diabetes mellitus3 (9)1 (3)0.32 HIV infection1 (3)2 (6)0.98 Obesity0 (0)1 (3)0.31 Cerebrovascular disease0 (0)1 (3)0.31 Immunosuppressive therapy2 (6)2 (6)0.98Prior to ICU admission Fever29 (85)31 (94)0.25 Headache12 (35)14 (42)0.55 Digestive signs25 (73)16 (48)0.04 NSAIDs consumption5 (56)4 (44)0.70 General practitioner visit in the prior 48 h10 (29)7 (21)0.44 Purpura before ICU admission25 (73)13 (39)0.01 Antibiotic therapy before ICU-admission25 (73)21 (64)0.38 Dysphagia/odynophagia2 (6)1 (3)0.57 Myalgia8 (23)4 (12)0.22 Arthralgia4 (6)1 (3)0.17 Lower limb pain13 (38)4 (12)0.01At ICU admission Coma Glasgow score14 \[13--15\]15 \[13--15\]0.99 Temperature, °C38.3 \[37.4--39.0\]38.6 \[38.0--40.0\]0.11 Neck stiffness4 (12)2 (6)0.41 Lower limb hyperalgesia14 (41)7 (21)0.08Biological data at ICU admission Leukocytes count, 10^3^ mm^−3^10.9 \[6.0--14.9\]9.7 \[1.6--21.0\]0.34 Platelets count, 10^3^ mm^−3^32 \[19--49\]36 \[19--67\]0.74 C-reactive protein, mg/L176 ± 86276 ± 1550.01 Procalcitonin, ng/mL113.5 ± 66.596.2 ± 59.00.73 Serum urea, mmol/L13.0 \[11.1--19.0\]12.0 \[8.6--15.0\]0.14 Serum creatinine, μmoL/L257 \[195--310\]211 \[174--303\]0.22 Prothrombin time, %24 \[14--35\]33 \[18--48\]0.12 Fibrinogen, g/L0.6 \[0.4--1.7\]2.0 \[0.9--3.4\]0.04 Arterial lactate, mmol/L8.0 \[4.9--10.0\]7.4 \[5.6--11.9\]0.74 Troponin, mg/L0.2 \[0.1--2.6\]1.0 \[0.1--35.7\]0.55 Creatine kinase, IU/L677 \[210--7825\]812 \[377--4355\]0.75Microbiological data Bacteraemia31 (91)27 (82)0.26 Lumbar puncture performed13 (38)16 (48)0.40 CSF white blood cell counts, 10^3^ mm^−3^3 \[1--5\]7 \[3--277\]0.06 Meningitis^b^2 (17)6 (43)0.15 Positive culture6 (46)5 (31)0.41*Abbreviations*: *CSF* cerebrospinal fluid, *ICU* intensive care unit, *NSAID* nonsteroidal anti-inflammatory drugs, *SAPS* Simplified Acute Physiology Score, *SOFA* Sequential Organ Failure Assessment; ^a^other than asplenia/hyposplenia; ^b^defined as ten or more cell/mm^3^ in cerebrospinal fluid Fig. 1Flow chart of adult patients with pneumococcal *purpura fulminans* with asplenia/hyposplenia (*n* = 34) or eusplenia (*n* = 33)

Clinical presentation, biological and microbiological features in asplenic/hyposplenic and eusplenic patients with pneumococcal purpura fulminans {#Sec8}
-------------------------------------------------------------------------------------------------------------------------------------------------

Clinical presentation did not significantly differ between asplenic/hyposplenic and eusplenic patients, except for digestive symptoms (*n* = 25/34, 73% vs. *n* = 16/33, 48%; *p* = 0.04) and lower limb pain (*n* = 13/34, 38% vs. *n* = 4/33, 12%; *p* = 0.01), which were more frequently reported in the former than in the latter. Purpura was also more frequently reported before ICU admission in asplenic/hyposplenic patients than in their counterparts (*n* = 25/34, 73% vs. *n* = 13/33, 39%; *p* = 0.01) (Table [2](#Tab2){ref-type="table"}). Biological and microbiological data did not differ between asplenic/hyposplenic and eusplenic patients. The rate of bacteremia was \> 80% but did not significantly differ between hyposplenic/asplenic and eusplenic patients (*n* = 31/34, 91% vs. *n* = 27/33, 82%; *p* = 0.26). There was no significant difference between groups regarding antibiotic therapy before ICU admission (*n* = 25/35, 73% vs. *n* = 21/33, 64%, *p* = 0.38), and all patients received a beta-lactam antibiotic in the ICU. Details regarding comorbidities, ICU scores, clinical presentation, and biological and microbiological data were provided in Table [2](#Tab2){ref-type="table"}.

Management, organ supports and outcomes in asplenic/hyposplenic and eusplenic patients with pneumococcal purpura fulminans {#Sec9}
--------------------------------------------------------------------------------------------------------------------------

The rates of invasive mechanical ventilation, renal replacement therapy, systolic myocardial dysfunction, and platelet or plasma transfusions did not differ between asplenic/hyposplenic and eusplenic patients (Table [3](#Tab3){ref-type="table"}), nor did the rate of limb amputation (*n* = 9/34, 26% vs. 15/33, 45%; *p* = 0.11) or hospital mortality (*n* = 20/34, 59% vs. *n* = 15/33, 45%; *p* = 0.27) (Fig. [2](#Fig2){ref-type="fig"}). Among asplenic/hyposplenic patients, hospital mortality did not differ between vaccinated and unvaccinated patients (*n* = 4/9, 44% vs. *n* = 14/22, 63%; *p* = 0.60). Outcome did not differ between hyposplenic and asplenic patients regarding limb amputations (*n* = 1/5, 20% vs. 8/29, 28%; *p* = 0.78) and hospital mortality (*n* = 3/5, 60% vs. 17/29, 59%; *p* = 0.98). More details regarding management, organ supports, and outcomes are provided in Table [3](#Tab3){ref-type="table"}. Table 3Management, organ supports and outcomes in patients with pneumococcal purpura fulminans having asplenia/hyposplenia (*n* = 34) or eusplenia (*n* = 33)Hypo/asplenia, *N* = 34Eusplenia, *N* = 33*p*Invasive mechanical ventilation32 (94)33 (100)0.16Duration of mechanical ventilation, days11 \[2--33\]9 \[4--17\]0.56ARDS20 (59)14 (42)0.18Renal replacement therapy22 (65)23 (70)0.66Lowest LVEF30 \[29--50\]26 \[11--53\]0.11Systolic myocardial dysfunction (LVEF\< 45%)18 (72)17 (71)0.93Inotropic agent17 (61)18 (62)0.92ECMO0 (0)6 (18)0.01Steroids for septic shock or meningitis25 (73)20 (61)0.26Activated protein C6 (18)3 (9)0.31Platelets transfusion22 (65)24 (73)0.48Plasma transfusion22 (65)22 (67)0.87Duration of vasopressor therapy, days5 \[2--13\]5 \[3--7\]0.41Duration of ICU stay, days9 \[2--45\]15 \[4--32\]0.96Limb amputation, %9 (26)15 (45)0.11In-hospital mortality, %20 (59)15 (45)0.27Abbreviations: *ARDS* acute respiratory distress syndrome, *LVEF* left ventricle ejection fraction, *ECMO* extra-corporeal membrane oxygenation, *ICU* intensive care unit Fig. 2Comparison of outcomes between asplenic or hyposplenic (*n* = 34) and eusplenic (*n* = 33) patients with pneumococcal *purpura fulminans*

Discussion {#Sec10}
==========

We report on the first multicenter cohort of adult patients admitted to the ICU for a pneumococcal purpura fulminans. The main results are as follows: (1) half of pneumococcal purpura fulminans occurred in asplenic or hyposplenic patients, (2) pneumococcal vaccination coverage was only 29% in adult asplenic/hyposplenic patients with pneumococcal purpura fulminans, (3) the time interval between asplenia/hyposplenia and pneumococcal purpura fulminans was 20 years, and (4) outcomes did not differ between patients with or without asplenia/hyposplenia. These results must be interpreted with caution due to the relatively small number of patients included, which limited our ability to show significant statistical differences between groups. Our study is, to the best of our knowledge, the first one to compare clinical features and outcomes of patients with pneumococcal purpura fulminans according to the presence/absence of a spleen, rendering comparisons with other studies difficult.

The median time interval between asplenia/hyposplenia and pneumococcal purpura fulminans observed in our study was 20 years, with only very few patients with pneumococcal purpura fulminans occurring within the 2 years following splenectomy or hyposplenia. This time interval is longer than the 5.75 years time interval observed in a recent prospective multicenter German study on overwhelming post-splenectomy infection from every cause and pathogen \[[@CR2]\]. It is commonly accepted that the greatest risk of overwhelming post-splenectomy infection is maximal within the first 2 years after splenectomy \[[@CR11]--[@CR13]\]. However, most of these studies \[[@CR11]--[@CR13]\] included immediate post-operative infections and had a limited follow-up duration, potentially underestimating the risk of late overwhelming post-splenectomy infection. The time interval observed in our cohort highlights that the risk of overwhelming post-splenectomy infection remains lifelong \[[@CR3], [@CR4], [@CR14], [@CR15]\].

In the present study, only 35% of the patients with asplenia or hyposplenia had received a pneumococcal vaccination despite current recommendations of the Centers for Disease Control and Prevention \[[@CR16]\]. However, it is worth noticing that 2/34 (6%) patients were not aware of their asplenic status since asplenia was diagnosed in the ICU and revealed by the pneumococcal purpura fulminans episode. Moreover, given the wide study period (17 years), recommendations about pneumococcal vaccination may have varied over time. The vaccination rate observed in our cohort is consistent with the 31% rate reported by Waghorn et al. in a series of 77 patients with overwhelming post-splenectomy infection \[[@CR3]\]. In a recent multicenter German cohort study including 52 patients with overwhelming post-splenectomy infection, only 11 (21%) had received a pneumococcal vaccination within the past 5 years. In the global population of splenectomized patients without infection, the coverage of pneumococcal vaccination rates is as high as 80% \[[@CR17], [@CR18]\]. Our finding of one third of the asplenic/hyposplenic patients with pneumococcal purpura fulminans having received a pneumococcal vaccination emphasizes that pneumococcal vaccination may reduce but does not abolish the risk of overwhelming post-splenectomy infection in splenectomized patients.

Our study showed similar severity levels and outcomes between patients with and without asplenia/hyposplenia. This observation is in line with a prospective multicenter German cohort study reporting a similar ICU, 7-day or 28-day mortality between patients with overwhelming post-splenectomy infection (from every cause and pathogen) and matched patients without asplenia or hyposplenia \[[@CR2]\]. Similarly, a large prospective Canadian cohort study including 2435 patients with invasive pneumococcal disease over a 15-year period reported on similar in-hospital mortality rates between asplenic/hyposplenic and eusplenic non-ICU patients \[[@CR19]\]. This observation underlines the fact that asplenia is a risk factor for severe pneumococcal sepsis but seems not to worsen the course of a declared sepsis, pointing out that our efforts must focus on preventing the disease. In this regard, a retrospective Australian before-after study recently showed that including patients in a registry of asplenic patients (with educational kit containing information sheet, alert cards regarding the history of splenectomy, educational DVD, personalized vaccine report, information regarding antibiotic prophylaxis, emergency plan in case of fever, newsletter to their general practitioners with updates regarding recommended vaccinations and booster doses) was associated with a significant reduction in the incidence of infections caused by encapsulated bacteria after splenectomy \[[@CR4]\].

Limitations {#Sec11}
-----------

Our study certainly suffers from several limitations. This was a retrospective study with inherently associated bias, as well as missing data and possible associated errors in data abstraction. However, due to the extreme rarity of pneumococcal purpura fulminans, a prospective study would be hardly feasible. A previous prospective multicenter study on overwhelming post-splenectomy infection in 173 German ICUs prematurely ended due to slow recruitment \[[@CR2]\]. Abdominal CT scan and detection of Howell-Jolly bodies in peripheral blood smears or counting of pitted erythrocytes by phase-interference microscopy was not routinely performed. Therefore, we cannot exclude that patients included in the eusplenic group had an unknown asplenia potentially related to congenital asplenia or other diseases (severe celiac disease, inflammatory bowel disease, Whipple's disease, amyloidosis, Sjögren's syndrome, HIV infection, cirrhosis) associated with hyposplenism or splenic atrophy \[[@CR5], [@CR20]\]. However, only 15% (*n* = 5/33) of the eusplenic patients had pre-existing diseases potentially associated with hyposplenism (ulcerative colitis *n* = 1, Sjögren's syndrome *n* = 1, HIV infection *n* = 2, cirrhosis *n* = 1). Because the patients were recruited over a 17-year period in 55 centers, ICU procedures were inevitably heterogeneous. The serotypes of the *Streptococcus pneumoniae* strains involved was not available due to the retrospective nature of the study, precluding any comparison to be made between both groups of patients. Last, the absence of significant outcome differences observed between asplenic/hyposplenic and eusplenic patients may be due to a lack of power related to a relatively small number of included patients.

Our study also has some strengths, including the large number of centers and patients included for a very rare infectious disease \[[@CR6]\], the comparison between asplenic and non-asplenic patients, with a paucity of previously published data due to the rarity of overwhelming post-splenectomy infection \[[@CR2]\], the collection of pneumococcal vaccination status which is poorly reported, and the fact that the definitions used for inclusion of the patients were well-standardized, rendering the comparison of the two groups relevant.

Clinical implications {#Sec12}
---------------------

Asplenic or hyposplenic patients admitted to the ICU for a purpura fulminans seem to have a high risk of pneumococcal purpura fulminans. In patients surviving pneumococcal purpura fulminans, unknown congenital asplenia should be searched with abdominal CT-scan. Detecting Howell-Jolly bodies in peripheral blood smear and counting pitted erythrocytes by phase-interference microscopy may also help diagnosing hyposplenia \[[@CR5]\]. In such patients, pneumococcal vaccination seems welcomed in order to avoid recurrences of overwhelming post-splenectomy infection. As recommended by the Centers for Disease Control and Prevention 2019 guidelines \[[@CR16]\], patients with asplenia or hyposplenia should receive one dose of the 13-valent pneumococcal conjugate vaccine together with one (for persons aged ≥ 64 years) or two doses (for persons aged 19--64 years) of the 23-valent pneumococcal polysaccharide vaccine. Furthermore, continuing education is required to advise patients with a risk of severe infection inherent to asplenia and the need for immediate antibiotic therapy in case of fever, especially since it has been reported that 40 to 84% of splenectomized individuals were not aware of the infectious risks associated with their condition \[[@CR18], [@CR21]\]. In adult asplenic/hyposplenic patients, long-term antibiotic prophylaxis \[[@CR5]\] is still debated, except in those who survived overwhelming post-splenectomy infection \[[@CR20]\], a targeted subgroup of patients in whom such a strategy seems appropriate, although supported by a low evidence.

Conclusion {#Sec13}
==========

Half of pneumococcal purpura fulminans occurred in asplenic or hyposplenic patients, who had a poor vaccination coverage against *Streptococcus pneumoniae*. Half of pneumococcal purpura fulminans episodes occurred more than 20 years after splenectomy. Outcomes seemed not to differ between asplenic/hyposplenic and eusplenic patients.

ICU

:   Intensive care unit
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